We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · August 10, 2022

Efficacy of Cabozantinib as Second-Line Therapy Based on Type of First-Line Therapy Received

Clinical Genitourinary Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
CABOSEQ: The effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Clin Genitourin Cancer 2022 Jul 20;[EPub Ahead of Print], V Navani, JC Wells, DJ Boyne, et al

Further Reading